Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients

Haemophilia

Volumn 5, Issue 2, 1999, Pages 88-95

  Deitcher, Steven R ^a,b   Tuller, Janet ^a   Johnson, Julie A ^a,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

DDAVP; Factor VIII; Haemophilia; Pharmacokinetics; Von Willebrand factor

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN ACETATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; RISTOCETIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INFUSION; HEMOPHILIA A; HUMAN; IMMUNOASSAY; INTRANASAL DRUG ADMINISTRATION; MEAN RESIDENCE TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADMINISTRATION, INTRANASAL; ADULT; ANTIBODIES, MONOCLONAL; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; HEMOPHILIA A; HEMOSTATICS; HUMANS; LINEAR MODELS; RECOMBINANT PROTEINS; VON WILLEBRAND FACTOR;

EID: 0032908392     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1999.00282.x     Document Type: Article

References (26)

1. Lethagen S, Harris AS, Sjorin E, Nilsson IM. Intranasal and intravenous administration of desmopressin: effect on factor VIII/vWF, pharmacokinetics and reproducibility. Thromb Haemost 1987; 58: 1033-6.
2. Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988; 72: 1449-55.
3. Lethagen S, Harris AS, Nilsson IM. Intranasal desmopressin (DDAVP) by spray in mild hemophilia A and von Willebrand's disease type I. Blut 1990; 60: 187-91.
4. Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med 1991; 114: 563-8.
5. Mannucci PM, Ruggeri ZM, Pareti FI, Capitano A. 1-Deamino-8-d-arginine vasopressin: a new pharmacologic approach to the management of haemophilia and von Willebrand's disease. Lancet 1977; 1: 869-72.
6. Nilsson IM, Holmberg L, Åberg M, Vilhardt H. The release of plasminogen activator and factor VIII after injection of DDAVP in healthy human volunteers and in patients with von Willebrand's disease. Scand J Haematol 1980; 34: 351.
7. Mannucci PM, Canciani MT, Rota L, et al. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease. Br J Haematol 1981; 47: 283-93.
8. Lethagen S, Egervall K, Berntrop E, Bengtsson B. Desmopressin nasal spray. A dose-finding study in patients with mild hemophilia A and von Willebrand's disease. Haemophilia 1995; 1: 97-102.
9. Lethagen S, Nilsson IM. DDAVP-induced enhancement of platelet retention. Its dependence on platelet-von Willebrand factor and the platelet receptor GPIIb/IIIa. Eur J Haematol 1992; 49: 7-13.
10. Nilsson IM, Felding P, Timberg L, Jonsson S, Harris AS. Clinical experience with DDAVP. In: Ciavarella NL, Ruggen Z, Zimmerman TS, eds. Factor VIII von Willebrand factor. Biological and clinical advances. Proceedings of Barr International Conference. Milan: Wichtig Editore, 1986: 63-80.
11. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor: Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977; 60: 390-404.
12. Fass DN. Factor VIII structure and function. Ann NY Acad Sci 1991; 614: 76-88.
13. Koedam JA. Interaction between factor VIII and vWF. PhD thesis. University of Utrecht, the Netherlands, 1989.
14. Fay PJ, Coumans J-V, Walker FJ. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 1991; 266: 2172-7.
15. Anderson L-O, Brown JE. Interaction of factor VIII-von Willebrand factor with phospholipid vesicles. Biochem J 1981; 200: 161-7.
16. Nesheim M, Pittman DD, Fass DN, et al. The effect of von Willebrand factor on the binding of factor VIII to thrombin activated platelets. J Biol Chem 1991; 266: 17815-20.
17. Rosenberg JB, Foster PA, Kaufman RJ, et al. Intracellular traficking of factor VIII to von Willebrand factor storage granules. J Clin Invest 1998; 101: 613-24.
18. Hellstern P, Kiehl R, Miyashita C, et al. Factor VIII:C recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A. comparison of one-stage assay, two-stage assay and a chromogenic substrate assay. Thromb Haemost 1986; 56: 353-9.
19. Tuddenham EGD, Lane RS, Roblat F, et al. Response to infusions of polyelectrolyte fractionated human Factor VIII concentrate in human haemophilia A and von Willebrand's disease. Br J Haematol 1982; 52: 259-67.
20. Ramsey R, Evatt BL. Rapid assay for von Willebrand factor activity using formalin-fixed platelets and microtitration technique. Am J Clin Path 1979; 72: 996-9.
21. Laurell CS. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1965; 15: 45-52.
22. Morfini M, Messori LA. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Thromb Haemost 1991; 66: 384-6.
23. Matucci M, Messori A, Donati-Cori G, et al. Kinetic evaluation of four factor VIII concentrates by model-independent methods. Scand J Haematol 1985; 34: 22-8.
24. Fijnvandraat K, Peters M, Ten Cate JW. Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 1995; 91: 474-6.
25. Vlot AJ, Koppelman SJ, Meijers JCM, et al. Kinetics of factor VIII-von Willebrand factor association. Blood 1996; 87: 1809-16.
26. Heijnen HFG, Koedam JA, Sandberg H, Beeser-Visser NH, Slot JW, Sixma JJ. Characterization of human factor VIII and interaction with von Willebrand factor. Eur J Biochem 1990; 194: 491-8.